BR112023025841A2 - Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma - Google Patents

Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma

Info

Publication number
BR112023025841A2
BR112023025841A2 BR112023025841A BR112023025841A BR112023025841A2 BR 112023025841 A2 BR112023025841 A2 BR 112023025841A2 BR 112023025841 A BR112023025841 A BR 112023025841A BR 112023025841 A BR112023025841 A BR 112023025841A BR 112023025841 A2 BR112023025841 A2 BR 112023025841A2
Authority
BR
Brazil
Prior art keywords
crystalline form
tolebrutinib
preparation
drug
pharmaceutical composition
Prior art date
Application number
BR112023025841A
Other languages
English (en)
Portuguese (pt)
Inventor
Jiaming Shi
Jing Zhang
Minhua Chen
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112023025841A2 publication Critical patent/BR112023025841A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023025841A 2021-06-11 2022-06-02 Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma BR112023025841A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110652005 2021-06-11
CN202110690510 2021-06-22
CN202111326112 2021-11-10
PCT/CN2022/096779 WO2022257845A1 (zh) 2021-06-11 2022-06-02 Tolebrutinib的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112023025841A2 true BR112023025841A2 (pt) 2024-03-05

Family

ID=84425691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025841A BR112023025841A2 (pt) 2021-06-11 2022-06-02 Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma

Country Status (12)

Country Link
US (1) US20250034130A1 (https=)
EP (1) EP4353723A4 (https=)
JP (1) JP2024521412A (https=)
KR (1) KR20240021217A (https=)
CN (1) CN117897381A (https=)
AU (1) AU2022290946A1 (https=)
BR (1) BR112023025841A2 (https=)
CA (1) CA3221129A1 (https=)
CO (1) CO2024000054A2 (https=)
IL (1) IL309263A (https=)
MX (1) MX2023014722A (https=)
WO (1) WO2022257845A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
US20250145618A1 (en) * 2021-12-21 2025-05-08 Principia Biopharma Inc. Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof
WO2023172663A1 (en) 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
AU2023408758A1 (en) * 2022-12-20 2025-07-31 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) * 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
UA124090C2 (uk) * 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
CA2986790A1 (en) * 2015-06-26 2016-12-29 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
BR112022014058A2 (pt) * 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)

Also Published As

Publication number Publication date
EP4353723A4 (en) 2025-06-25
EP4353723A1 (en) 2024-04-17
CO2024000054A2 (es) 2024-02-05
WO2022257845A1 (zh) 2022-12-15
CA3221129A1 (en) 2022-12-15
US20250034130A1 (en) 2025-01-30
KR20240021217A (ko) 2024-02-16
CN117897381A (zh) 2024-04-16
MX2023014722A (es) 2024-02-13
AU2022290946A1 (en) 2024-01-25
JP2024521412A (ja) 2024-05-31
IL309263A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
BR112023025841A2 (pt) Forma cristalina de tolebrutinibe, método de preparação para mesma e uso da mesma
BR112023021383A2 (pt) Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
BR112012030177A2 (pt) composto, uso do mesmo, e, composição farmacêutica
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
NZ607118A (en) C-met modulator pharmaceutical compositions
BRPI0511967B8 (pt) derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112015031878A2 (pt) composição farmacêutica
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
BR112022009705A2 (pt) Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
BR112022003562A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos
BR112013017302A2 (pt) formulações de imunossupressor
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR0210595A (pt) Regime de dosagem e composição farmacêutica para contracepção de emergência
BR0010257A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
BR112022004099A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
MX2025002790A (es) Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos
CN104173332B (zh) 银杏内酯类化合物的用途
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
BR112015018144A8 (pt) composição de emulsão água/óleo farmacêutica estável com gotículas de óleo manométricas, método para fazer a mesma e alta dose única de clopidogrel usada para tratar um paciente
BR112022018173A2 (pt) Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo
BR0311384A (pt) Composto, processo para preparar o mesmo, formulação farmacêutica, uso de um composto, e, método para tratamento ou profilaxia de condições em que a inibição da carboxipeptidase u é benáfica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PRINCIPIA BIOPHARMA INC. (US)

B25G Requested change of headquarter approved

Owner name: PRINCIPIA BIOPHARMA INC. (US)